U01CA272610

Elucidating and targeting tumor dependencies and drug resistance determinants at the single cell level - cancer targets fall into two major categories: oncoproteins that elicit tumor essentiality due to their direct role in tumorigenesis or tumor maintenance (oncogene dependencies) and proteins that elicit synthetic lethality with oncogene mutations but are not themselves mutated (non-oncogene dependencies).

Unfortunately, clonal selection and inherent cancer cell plasticity—as well as the ability of cancer cells to undergo adaptation and reprogramming to drug resistant states, following treatment—are currently challenging the concept of individual proteins as effective therapeutic targets for an entire tumor mass—especially if identified from bulk tissue analyses.

Indeed, despite several successes, only 5% – 11% of cancer patients benefit from targeted therapy, based on progression free survival, often with no substantial overall survival differences; while promising, immune therapy is also subject to selective response and relapse.

To address these challenges, our proposal will study a more universal class of mutation-agnostic, non-oncogene dependencies implemented by tightly-autoregulated sets of master regulator (MR) proteins that we have called tumor checkpoint (TC) modules.

We have shown that MR proteins mechanistically implement a tumor cell’s transcriptional state by canalizing the effect of mutations and aberrant signals in their upstream pathways. As such, within the context of a transcriptionally-distinct tumor subtype, they represent largely mutation-agnostic dependencies.

Our proposal will thus focus on the elucidation and pharmacological targeting of MRs and TC-modules at the single cell level, within molecularly distinct, yet co-existing tumor subpopulations. This will lead to design of successful combination therapy approaches and will help elucidate and pharmacologically target mechanisms of drug resistance and cell adaptation.

To accomplish these goals, we will extend a highly successful, network-based framework developed by our CTD2 center, for the elucidation, validation, and pharmacological targeting of MR proteins and TC-modules.

Indeed, we have shown that genetic or pharmacological targeting of this new class of tumor dependencies can induce collapse of TC-module activity and induce loss of tumor viability in a wide range of malignancies, ranging from glioblastoma, neuroblastoma, and neuroendocrine tumors, to prostate and breast adenocarcinoma, among many others.

In particular, analysis of 25 TCGA cohorts has identified 112 transcriptionally distinct tumor subtypes, each one regulated by a distinct subtype-specific TC-module, which was independent of patient-specific mutations. These methodologies are especially relevant in rare, aggressive tumors—including several pediatric malignancies—where cohort size may be too small to support correlative analyses.

Critically, these studies have led to the development of two NY/CA Dpt. of Health approved, CLIA-compliant tests, Oncotarget and Oncotreat, whose predictions have spurred several clinical trials.

These approaches will be extended to elucidate TC-module dependencies and to develop drug sensitivity biomarkers at the single cell level.

The Trustees Of Columbia University In The City Of New York

TO IMPROVE SCREENING AND EARLY DETECTION STRATEGIES AND TO DEVELOP ACCURATE DIAGNOSTIC TECHNIQUES AND METHODS FOR PREDICTING THE COURSE OF DISEASE IN CANCER PATIENTS. SCREENING AND EARLY DETECTION RESEARCH INCLUDES DEVELOPMENT OF STRATEGIES TO DECREASE CANCER MORTALITY BY FINDING TUMORS EARLY WHEN THEY ARE MORE AMENABLE TO TREATMENT. DIAGNOSIS RESEARCH FOCUSES ON METHODS TO DETERMINE THE PRESENCE OF A SPECIFIC TYPE OF CANCER, TO PREDICT ITS COURSE AND RESPONSE TO THERAPY, BOTH A PARTICULAR THERAPY OR A CLASS OF AGENTS, AND TO MONITOR THE EFFECT OF THE THERAPY AND THE APPEARANCE OF DISEASE RECURRENCE. THESE METHODS INCLUDE DIAGNOSTIC IMAGING AND DIRECT ANALYSES OF SPECIMENS FROM TUMOR OR OTHER TISSUES. SUPPORT IS ALSO PROVIDED FOR ESTABLISHING AND MAINTAINING RESOURCES OF HUMAN TISSUE TO FACILITATE RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.396 - Cancer Biology Research

National Cancer Institute (NCI) [HHS - NIH]

New York, New York 100323802 United States

Single Zip Code

Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed) (PAR-21-274)

Amendment Since initial award the total obligations have increased 288% from $991,182 to $3,840,901.